Bolyn Hubby, Ph.D.
SVP, Research & Public-Private Partnerships
Bolyn Hubby, Ph.D., is Senior Vice President of Research and Public-Private Partnerships at Vir. Dr. Hubby joined Vir through the acquisition of Agenovir, a gene editing company, where she was CSO. Her career has focused on driving innovative technologies from concept to clinic to address unmet needs in infectious disease and oncology.
Prior to Agenovir, Dr. Hubby was the Vice President of Vaccines and Antimicrobials at Synthetic Genomics, where she and her colleagues advanced the company’s core synthetic biology technology for influenza vaccines into the clinic and developed novel RNA vaccine and antimicrobial platforms to address the rapid spread of infectious disease and the growing global threat of antibiotic resistance. Prior to Synthetic Genomics, Dr. Hubby served as Executive Director of Vaccines at Liquidia Technologies, Inc., where she and her team built a portfolio of programs focused on new approaches to protein, polysaccharide, and RNA-vectored vaccines targeting bacterial and viral pathogens. Before Liquidia, Dr. Hubby was Head of Discovery Immunology at AlphaVax, Inc., where she helped advance an RNA-based viral vector platform to develop vaccines for infectious diseases, biodefense and cancer.
Dr. Hubby received her Ph.D. from the University of Georgia, Department of Cellular Biology and Center for Tropical and Emerging Diseases.